L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis
Status:
Unknown status
Trial end date:
2019-11-01
Target enrollment:
Participant gender:
Summary
This study aimed to investigate the efficacy and safety of Pegaspargase together with
liposomal doxorubicin, etoposide and high dose methylprednisolone (L-DEP) as a salvage
therapy for refractory Epstein Barr virus-induced hemophagocytic lymphohistiocytosis.